Addrenex makes appointments
This article was originally published in Scrip
Addrenex Pharmaceuticals, a two-year-old US firm, has appointed Steven Butts vice-president of commercial affairs, Dr Gary Bream senior director of scientific affairs, and Yuki Prescott clinical trials manager. Mr Butts has worked at Biobehavioral Diagnostics and Lilly, while Dr Bream and Ms Prescott most recently served at Constella. Addrenex has filed a sustained-release clonidine product, CloniBID, for US approval in hypertension, and has an extended-release clonidine, Clonicel, in Phase III trials for attention deficit hyperactivity disorder; both products will be marketed by licensee Sciele Pharma.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.